Literature DB >> 24649857

Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD.

Umberto Vespasiani-Gentilucci1, Simone Carotti, Giuseppe Perrone, Chiara Mazzarelli, Giovanni Galati, Andrea Onetti-Muda, Antonio Picardi, Sergio Morini.   

Abstract

BACKGROUND & AIMS: Notwithstanding evidences implicating the lipopolysaccharides (LPS)/toll-like receptor-4 (TLR4) axis in the pathogenesis of NAFLD, there are no studies aimed to characterize hepatic TLR4 expression in NAFLD patients. We aimed to analyse hepatic TLR4 expression and to verify its relationship with disease activity/evolution in NAFLD patients.
METHODS: Liver tissue from 74 patients with NAFLD and 12 controls was analysed by immunohistochemistry (IHC) for TLR4, α-smooth muscle actin (α-SMA) and cytokeratin-7. IHC for α-SMA was used to evaluate activation of fibrogenic cells (hepatic stellate cells and portal/septal myofibroblasts), that for cytokeratin-7 to count hepatic progenitor cells and bile ducts/ductules, and that for CD68, in a subgroup of 27 patients, for detecting macrophages. Serum LPS-binding protein (LBP), a sensitive marker of LPS activity, was determined in 36 patients and 32 controls.
RESULTS: As confirmed by double-labelling experiments, the highest level of TLR4 expression was observed in hepatic progenitor cells, biliary cells and portal/septal macrophages. TLR4-positive hepatic progenitor cells and bile ducts/ductules correlated with portal/interface inflammation, activity of fibrogenic cells and fibrosis (P < 0.001). Also the score of TLR4 positivity of porto-septal inflammatory infiltrate correlated with number of hepatic progenitor cells and bile ducts/ductules, activity of fibrogenic cells and fibrosis (P < 0.01). Serum LBP was increased in patients compared to controls (P < 0.001), and correlated with portal/interface inflammation, activity of portal/septal myofibroblasts and fibrosis (all P < 0.05).
CONCLUSIONS: TLR4 expression by regenerating and inflammatory cells at the porto-septal and interface level, favoured by increased LPS activity, is associated with activation of fibrogenic cells and the degree of fibrosis.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ductular reaction; fibrosis; hepatic progenitor cells; hepatic stellate cells; lipopolysaccharides; myofibroblast; portal inflammation

Mesh:

Substances:

Year:  2014        PMID: 24649857     DOI: 10.1111/liv.12531

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  31 in total

Review 1.  Effects of red wine on postprandial stress: potential implication in non-alcoholic fatty liver disease development.

Authors:  Ilaria Peluso; Husseen Manafikhi; Raffaella Reggi; Maura Palmery
Journal:  Eur J Nutr       Date:  2015-03-16       Impact factor: 5.614

2.  European Obesity Summit (EOS) - Joint Congress of EASOand IFSO-EC, Gothenburg, Sweden, June 1 - 4, 2016: Abstracts.

Authors: 
Journal:  Obes Facts       Date:  2016-05-25       Impact factor: 3.942

3.  Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4.

Authors:  Guang-Nian Zhao; Peng Zhang; Jun Gong; Xiao-Jing Zhang; Pi-Xiao Wang; Miao Yin; Zhou Jiang; Li-Jun Shen; Yan-Xiao Ji; Jingjing Tong; Yutao Wang; Qiao-Fang Wei; Yong Wang; Xue-Yong Zhu; Xin Zhang; Jing Fang; Qingguo Xie; Zhi-Gang She; Zhihua Wang; Zan Huang; Hongliang Li
Journal:  Nat Med       Date:  2017-05-08       Impact factor: 53.440

Review 4.  The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease.

Authors:  Marina Nati; Kyoung-Jin Chung; Triantafyllos Chavakis
Journal:  J Innate Immun       Date:  2021-08-24       Impact factor: 7.349

5.  High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice.

Authors:  Xiaodong Ge; Elena Arriazu; Fernando Magdaleno; Daniel J Antoine; Rouchelle Dela Cruz; Neil Theise; Natalia Nieto
Journal:  Hepatology       Date:  2018-11-13       Impact factor: 17.425

6.  Starring role of toll-like receptor-4 activation in the gut-liver axis.

Authors:  Simone Carotti; Michele Pier Luca Guarino; Umberto Vespasiani-Gentilucci; Sergio Morini
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 7.  Gut microbiome, liver immunology, and liver diseases.

Authors:  Rui Wang; Ruqi Tang; Bo Li; Xiong Ma; Bernd Schnabl; Herbert Tilg
Journal:  Cell Mol Immunol       Date:  2020-12-14       Impact factor: 11.530

8.  High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments.

Authors:  Hsiao-Ching Nien; Shih-Jer Hsu; Tung-Hung Su; Po-Jen Yang; Jin-Chuan Sheu; Jin-Town Wang; Lu-Ping Chow; Chi-Ling Chen; Jia-Horng Kao; Wei-Shiung Yang
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

Review 9.  The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Detlef Schuppan; Henning Grønbæk; Konstantin Kazankov; Simon Mark Dahl Jørgensen; Karen Louise Thomsen; Holger Jon Møller; Hendrik Vilstrup; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-03       Impact factor: 46.802

10.  Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury.

Authors:  Elena Arriazu; Xiaodong Ge; Tung-Ming Leung; Fernando Magdaleno; Aritz Lopategi; Yongke Lu; Naoto Kitamura; Raquel Urtasun; Neil Theise; Daniel J Antoine; Natalia Nieto
Journal:  Gut       Date:  2016-01-27       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.